

NBI-6024

Cat. No.:	HY-106171
CAS No.:	239480-61-6
Molecular Formula:	C ₆₆ H ₁₁₂ N ₂₀ O ₂₁
Molecular Weight:	1521.72
Sequence Shortening:	SHLVEALALVAGERG
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	NBI-6024, an altered peptide ligand (APL), is an epitope recognized by inflammatory interferon-gamma-producing T helper lymphocytes in type 1 diabetic patients ^{[1][2]} .	
In Vivo	NBI-6024 (0.005-20 mg/kg, s.c.) delays the onset and reduces the incidence of diabetes in mice ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Nonobese diabetic (NOD) mice ^[2]
	Dosage:	0.005, 0.05, 0.5, 5, 10, 20 mg/kg
	Administration:	Subcutaneous injection (s.c.)
	Result:	Observed dose-dependent induction of responsiveness to the immunizing antigen at 5, 10, 20 mg/kg (tested by culturing spleen cells pooled from mice).

REFERENCES

[1]. D G Alleva et al. Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope. Scand J Immunol. 2006 Jan;63(1):59-69.

[2]. Alleva DG, et al. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes. 2002 Jul;51(7):2126-34.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA